You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

TransCon TLR7/8 Agonist

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Head and Neck Tumors Trial (TransCon TLR7/8 Agonist, Pembrolizumab, TransCon IL-2 ß/?)

Not yet recruiting
  • Head and Neck Neoplasms
  • TransCon TLR7/8 Agonist
  • +2 more
  • (no location specified)
Aug 4, 2023

Advanced Solid Tumor, Locally Advanced Solid Tumor, Metastatic Solid Tumor Trial in Australia, United States (TransCon IL-2 ß/?,

Recruiting
  • Advanced Solid Tumor
  • +7 more
  • TransCon IL-2 β/γ
  • +4 more
  • Boston, Massachusetts
  • +7 more
Nov 16, 2022

Advanced Solid Tumor, Locally Advanced Solid Tumor, Metastatic Solid Tumor Trial in Australia, United States (TransCon TLR7/8

Recruiting
  • Advanced Solid Tumor
  • +6 more
  • Duarte, California
  • +12 more
Sep 21, 2022

Myeloid Malignancies, Lymphoid Malignancies Trial in Durham (NK Cell enriched-DLI only, NK-DLI + DUK-CPG-001)

Recruiting
  • Myeloid Malignancies
  • Lymphoid Malignancies
  • NK Cell enriched-DLI only
  • NK-DLI + DUK-CPG-001
  • Durham, North Carolina
    Duke University Health System
Mar 8, 2022

HIV Trial in South Africa, United States (sD-NP-GT8 DNA, IL-12 DNA, Trimer 4571)

Not yet recruiting
  • HIV Infections
  • sD-NP-GT8 DNA
  • +4 more
  • Birmingham, Alabama
  • +5 more
Mar 10, 2023

Carcinoma, Hepatocellular, Biliary Tract Cancer, Secondary Liver Cancer Trial in Worldwide (RO7119929, Tocilizumab)

Completed
  • Carcinoma, Hepatocellular
  • +3 more
  • Duarte, California
  • +9 more
Jan 27, 2023

Breast Cancer, Metastatic Breast Cancer, Recurrent Breast Cancer Trial in New York (Radiation, Imiquimod, Cyclophosphamide)

Completed
Has Results
  • Breast Cancer
  • +2 more
  • Radiation
  • +2 more
  • New York, New York
    New York University Medical Center
Oct 25, 2021

HIV-1-infection Trial in Umlazi (Vesatolimod, VRC07523LS, CAP256V2LS)

Recruiting
  • HIV-1-infection
  • Umlazi, South Africa
    FRESH Clinical Research Site: Females Rising through Education,
Jan 4, 2023

Metastatic Prostate Adenocarcinoma, Stage IV Prostate Cancer AJCC v8 Trial in Atlanta (VLP-encapsulated TLR9 Agonist CMP-001,,

Not yet recruiting
  • Metastatic Prostate Adenocarcinoma
  • Stage IV Prostate Cancer AJCC v8
  • VLP-encapsulated TLR9 Agonist CMP-001,
  • Nivolumab
  • Atlanta, Georgia
    Emory University Hospital/Winship Cancer Institute
Aug 26, 2022

Locally Advanced Malignant Solid Tumor, Metastatic Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8 Trial in United

Recruiting
  • Locally Advanced Malignant Solid Neoplasm
  • +3 more
  • Agonistic Anti-OX40 Monoclonal Antibody INCAGN01949
  • VLP-encapsulated TLR9 Agonist CMP-001
  • Scottsdale, Arizona
  • +3 more
Jun 1, 2022

Hepatitis B, HIV Trial in Worldwide (Selgantolimod, Placebo)

Recruiting
  • Hepatitis B
  • HIV Infections
  • San Diego, California
  • +35 more
Jan 31, 2023

COVID-19 Trial (APR002)

Not yet recruiting
  • COVID-19
  • (no location specified)
Feb 24, 2022

Biomarkers of Trained Immunity Following MMR Vaccination

Completed
  • Covid19
  • Heterologous stimuli
  • Neutralization assay
  • Saint Louis, Missouri
    Washington University School of Medicine
Nov 24, 2021

Asthma Trial in Germany, United Kingdom (GSK2245035 Nasal Spray Solution, Placebo Nasal Spray Solution)

Completed
Has Results
  • Asthma
  • GSK2245035 Nasal Spray Solution
  • Placebo Nasal Spray Solution
  • Frankfurt, Hessen, Germany
  • +5 more
Feb 26, 2021

Metastatic Pancreatic Adenocarcinoma, Refractory Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8 Trial in

Active, not recruiting
  • Metastatic Pancreatic Adenocarcinoma
  • +2 more
  • Nivolumab
  • +2 more
  • Sacramento, California
    University of California Davis Comprehensive Cancer Center
Dec 16, 2021

Solid Tumor Trial in Beijing (SHR2150, Anti-Cancer Agent)

Unknown status
  • Solid Tumor
  • Beijing, Beijing, China
    Biotherapeutic Department of Chinese PLA General Hospital
Oct 15, 2020

HIV/AIDS Trial in Spain (ChAdOx1.HTI, MVA.HTI, GS-9620)

Active, not recruiting
  • HIV/AIDS
  • ChAdOx1.HTI
  • +4 more
  • Badalona, Barcelona, Spain
  • +8 more
Jul 30, 2021

HIV-1-infection Trial in Brazil, United States (ChAdOx1.tHIVconsv1, ChAdOx1.HIVconsv62, MVA.tHIVconsv3)

Not yet recruiting
  • HIV-1-infection
  • ChAdOx1.tHIVconsv1
  • +7 more
  • San Diego, California
  • +11 more
Oct 4, 2023

Growth Hormone Deficiency, Pediatric, Endocrine System Diseases, Hormone Deficiency Trial in Worldwide (TransCon hGH)

Completed
Has Results
  • Growth Hormone Deficiency, Pediatric
  • +3 more
  • TransCon hGH
  • Birmingham, Alabama
  • +23 more
Dec 7, 2021

Growth Hormone Deficiency, Pediatric, hGH (Human Growth Hormone), Endocrine System Diseases Trial in Worldwide (Once weekly

Completed
Has Results
  • Growth Hormone Deficiency, Pediatric
  • +4 more
  • Once weekly subcutaneous injection of TransCon hGH
  • Once daily subcutaneous injection of Genotropin
  • Birmingham, Alabama
  • +52 more
Dec 6, 2021

Arterial Stiffness, Hypertension, Cardiovascular Diseases Trial in Prague (Cardiovascular fitness)

Active, not recruiting
  • Arterial Stiffness
  • +2 more
  • Cardiovascular fitness
  • Prague, Czechia
  • +1 more
Sep 14, 2023

Achondroplasia Trial in Parkville (TransCon CNP)

Recruiting
  • Achondroplasia
  • TransCon CNP
  • Parkville, Victoria, Australia
    Ascendis Pharma Investigational Site
Jun 30, 2023

Gastroparesis Trial in Worldwide (GSK962040 (5 mg tablet), GSK962040 (25 mg tablet), GSK962040 (125 mg tablet))

Completed
Has Results
  • Gastroparesis
  • GSK962040 (5 mg tablet)
  • +3 more
  • Concord, California
  • +21 more
Jul 13, 2021

Achondroplasia Trial (Navepegritide, Placebo for Navepegritide)

Not yet recruiting
  • Achondroplasia
  • (no location specified)
Oct 6, 2023

Fertility Trial in Barcelona (150µg CFA (Elonva®) at stimulation day (SD) 1 and 100µg CFA(Elonva®) at SD 5, 150µg CFA (Elonva®)

Not yet recruiting
  • Fertility
  • 150μg CFA (Elonva®) at stimulation day (SD) 1 and 100μg CFA(Elonva®) at SD 5
  • 150μg CFA (Elonva®) at SD 1 following by rFSH (Puregon®) 200IU daily from SD 8 until the day of the trigger
  • Barcelona, Spain
    Hospital Universitario Quiron Dexeus
Nov 10, 2023